Incidence of severe urinary tract infections not increased by initiating sodium-glucose cotransporter-2 inhibitors.
Recently, the Food and Drug Administration (FDA) issued an advisory that sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a risk of severe urinary tract infection (UTI) (1). They reported 19 patients with life-threatening sepsis due to UTI and severe pyelonephritis after initiating SGLT-2 inhibitors who required hospitalization. Some of them required admission to an intensive care unit or dialysis in order to treat acute renal failure.